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Pathways associated with reduced
quadriceps oxidative fibres and endurance
in COPD
Samantha A. Natanek*,#,", Harry R. Gosker", Ilse G.M. Slot", Gemma S. Marsh*,
Nicholas S. Hopkinson*, John Moxham+, Paul R. Kemp#,
Annemie M.W.J. Schols",1 and Michael I. Polkey*,1
ABSTRACT: Reduced quadriceps endurance in chronic obstructive pulmonary disease (COPD) is
associated with a predominance of type II glycolytic fibres over type I oxidative fibres (fibre shift)
and reduced muscle energy stores. The molecular mechanisms responsible for this remain
unknown. We hypothesised that expression of known regulators of type I fibres and energy
production in quadriceps muscle would differ in COPD patients with and without fibre shift.
We measured lung function, physical activity, exercise performance, quadriceps strength and
endurance (nonvolitionally) in 38 Global Initiative for Chronic Obstructive Lung Disease stage I–IV
COPD patients and 23 healthy age-matched controls. Participants underwent a quadriceps
biopsy: type I and II fibre proportions were determined using immunohistochemistry and fibre
shift defined using published reference ranges. Calcineurin A, phosphorylated AMP kinase
(phospho-AMPK)-a, protein kinase A-a catalytic subunits, modulators of calcineurin activity
and calmodulin, 14-3-3 proteins were measured by Western blotting, and myocyte-enriched
calcineurin-interacting protein-1 mRNA measured by quantitative PCR. Downstream, nuclear
myocyte enhancer factor-2 capable of DNA binding was quantified by transcription factor ELISA.
Unexpectedly, calcineurin expression was higher, while phospho-AMPK was lower, in COPD
patients with fibre shift compared to COPD patients without fibre shift. Phospho-AMPK levels
correlated with quadriceps endurance in patients.
Reduced phospho-AMPK may contribute to reduced quadriceps oxidative capacity and
endurance in COPD.
KEYWORDS: AMP kinase, calcineurin, myocyte enhancer factor-2, protein kinase A
R
educed quadriceps endurance is asso-
ciated with exercise limitation in chronic
obstructive pulmonary disease (COPD)
[1]. Underlying the loss of endurance is a
reduction in type I myosin and oxidative
enzymes [2], the hallmarks of the reduced
oxidative type I to glycolytic type II fibre ratio
observed in the quadriceps of COPD patients,
which we will refer to in this study as the
presence of fibre shift [3]. Type I fibres rely
exclusively on oxidative metabolism to generate
ATP, type IIx fibres depend on glycolysis, and
type IIa fibres utilise both oxidative and glyco-
lytic metabolism [4]. Since oxidative metabolism
generates several times more ATP than glycolysis
per molecule of glucose [5], type I fibres are
fatigue-resistant compared to type II fibres.
COPD patients, with their fewer oxidative fibres,
have fewer muscle energy stores and exhibit
metabolic stress from ATP depletion at rest and
at low workloads, unlike controls. Reduced
energy turnover may be exacerbated by reduced
insulin sensitivity in COPD [6]; insulin driving
cellular glucose uptake via the GLUT-4 receptor
[7]. Understanding mechanisms underlying these
changes may lead to treatments to improve
exercise capacity in patients with COPD.
Pathways influencing muscle type I fibre differ-
entiation during development, muscle oxidative
enzymes and energy production/glucose uptake
have been described in animal models (fig. 1) [8].
Calcineurin is a phosphatase which activates type
I fibre-specific gene expression in vitro and, when
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blocked, can produce type I to type II fibre shift in animals, for
example [9]. Calcineurin is activated by calcium bound to
calmodulin in response to muscle activity, and is inhibited by
endogenous protein inhibitors, particularly myocyte-enriched
calcineurin-interacting protein-1 (MCIP1) [10]. Calcineurin
stimulates targets including the myocyte enhancer factor
(MEF)2 and nuclear factor of activated T-cells (NFAT)
transcription factors. MEF2D and NFATc1 activate type I fibre
gene expression [11]. 14-3-3 proteins influence calcineurin
signalling by binding MCIP1 [12], releasing its inhibition of
calcineurin activity, and by inhibiting NFAT [13]. In addition,
calcineurin promotes cellular glucose uptake via the GLUT-4
receptor [9].
AMP kinase (AMPK) activates genes enhancing muscle
oxidative metabolism to increase exercise endurance in
animals [14], and induces muscle glucose uptake via GLUT-4
receptor transcription through a MEF2-dependent mechanism
[15]. It is activated by phosphorylation under conditions of
metabolic stress including exercise. Protein kinase A (PKA) is
an enzyme that mobilises glucose (e.g. by glycogenolysis) to
provide muscle with ATP during exercise [16].
This is the first study investigating the expression of
calcineurin, phospho-AMPK and PKA, and MEF2 DNA
binding in quadriceps muscle from COPD patients and healthy
controls. The rationale for investigating the three enzymes
was: 1) they are all responsive to muscle activity which is
decreased in COPD [17]; 2) they affect muscle energy production
and/or type I fibre specification; and 3) calcineurin and AMPK
both activate MEF2. We hypothesised that calcineurin and MEF2
expression would be reduced, but phospho-AMPK and PKA
expression would be increased in response to metabolic stress,
in the quadriceps muscle of COPD patients with fibre shift
compared to patients without fibre shift.
METHODS
Ethical approval
Ethical approval was received from the Royal Brompton and
Harefield NHS Trust (06/Q0404/35) and the Ealing and West
London Mental Health Trust Ethics Committees (06/Q0410/
54). Patients gave written, informed consent.
Participants
38 patients with COPD were recruited from clinics at the Royal
Brompton Hospital, London, UK. 23 healthy controls were
recruited by advertisement. Exclusion criteria were: diagnoses
of heart, renal or liver failure; systemic inflammatory, metabolic
or neuromuscular disorders (independently associated with
skeletal muscle abnormalities); warfarin therapy (bleeding risk
from biopsy); or a moderate/severe exacerbation (i.e. requiring
intervention) within the preceding 4 weeks. Specimens from
these participants have been used previously [18, 19].
Physiological measurements
Post-bronchodilator spirometry, lung volumes (plethysmo-
graphy) and diffusion capacity were measured according to
European Respiratory Society/American Thoracic Society
(ATS) guidelines [20–22], and arterialised capillary earlobe
blood gas tensions were recorded. Fat-free mass index (FFMI)
was calculated from bioelectrical impedance measurements
(Bodystat 1500; Bodystat, Douglas, UK) using a disease-specific
regression equation [23]. Physical activity was measured over
12 h on 2 days (Dynaport accelerometer; McRoberts, The Hague,
the Netherlands) as validated for COPD [24]. Quadriceps
strength was assessed by supine isometric maximal voluntary
contraction [25]. Quadriceps endurance was assessed by timing
the force decline to 80% of initial response during trains of
magnetic femoral nerve stimulation as described previously [2].
Exercise performance was assessed with a 6-min walk test [26]
and symptom-limited incremental cycle ergometry with mea-
surement of peak oxygen uptake [27].
Quadriceps sampling
Percutaneous biopsy of the vastus lateralis was performed
using the technique of BERGSTROM [28] after subjects had rested
for 20 min, on a day without strenuous physical activity.
Samples for histology and mRNA/protein analysis were
frozen in melting isopentane and liquid nitrogen, respectively,
prior to storing at -80uC (online supplementary material).
Measurement of quadriceps fibre type proportions and
fibre cross-sectional area
Immunohistochemistry using antibodies against type I and IIa
myosin and laminin was performed on transverse muscle
sections to calculate type I, IIa (both pure IIa and hybrid IIa/IIx
fibres, which could not be differentiated), IIx and hybrid I/IIa
fibre proportions and the median cross-sectional area (CSA) for
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FIGURE 1. In response to muscle activity, calcineurin (and also calcium-
calmodulin protein kinase IV, not shown here) signalling activates nuclear factor of
activated T-cells (NFAT) translocation to the nucleus and increases myocyte
enhancer factor (MEF)2 activation to drive oxidative muscle-specific gene
transcription. In response to energy depletion, phosphorylated AMP kinase
(phospho-AMPK) activates peroxisome proliferator-activated receptor c co-activator
(PGC)-1a and peroxisome proliferator-activated receptor (PPAR)-d to drive oxidative
muscle-specific gene transcription. Both calcineurin and phospho-AMPK upregu-
late GLUT-4 receptors, promoting muscle cell glucose uptake via MEF2. Protein
kinase A promotes mobilisation of glucose production by glycogenolysis at times of
increased requirement for energy production. Modified from [8].
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material) [29]. Fibre shift was defined by type I fibre proportions
falling below and/or type IIx fibre proportions falling above the
cut-off taken from healthy 60–70-year-olds [3].
Measurement of calcineurin A, phospho-AMPK-a, PKA-a
subunits, calmodulin and 14-3-3 proteins
Western blotting was performed with 20–50 mg protein from 38
patients and 23 controls (34 patients and 19 controls for
calcineurin, 24 patients and 23 controls for phospho-AMPK)
and results normalised by immunoblotting for a-tubulin
(online supplementary material). Expression of the catalyt-
ically active subunits calcineurin A, phospho-AMPK-a and the
predominant muscle isoform PKA-a was quantified.
Measurement of MEF2 in muscle nuclear extracts capable
of binding DNA
MEF2 (all subclasses) DNA-binding was quantified using
transcription factor ELISA (Panomics, Santa Clara, CA, USA)
in duplicate per sample (online supplementary material).
Quantity was proportional to the relative light unit fluores-
cence emitted.
Measurement of MCIP1 and myosin heavy chain I mRNA
Both MCIP1 and the myosin heavy chain I gene (MyH7) are
target genes of calcineurin. MyH7 transcripts indicate current
transcription supporting type I fibres, while type I fibre
proportion reflects transcription several weeks prior; hence
both were measured. mRNA was measured by quantitative
(q)PCR using SYBR green and normalised to acidic ribosomal
phosphoprotein PO [30] and b-2-microglobulin transcripts
using geNorm (online supplementary material) [31].
Statistics
Group differences in normally distributed, non-normally
distributed and categorical data were tested with the t-test,
Mann–Whitney U-test and Fisher’s exact test, respectively.
Spearman’s rank (r) correlation was calculated to assess
correlations. A two-tailed p-value of f0.05 was set as defining
statistical significance.
RESULTS
Characteristics of COPD patients compared to controls
Age and sex were not significantly different between patients
and controls. Patients had significantly reduced lung function,
arterialised oxygen tensions, FFMI, quadriceps strength and
endurance, physical activity and exercise performance com-
pared to controls (table 1). One (3%), nine (23%), 14 (37%) and
14 (37%) patients had Global Initiative for Chronic Obstructive
Lung Disease stage I, II, III and IV disease, respectively. As a
group, COPD patients had a significantly lower type I and
higher type IIa and IIx fibre proportion, and a reduced type
IIx fibre CSA compared with controls, consistent with
previous observations (table 2) [3, 32]. 13 (34%) patients had
fibre shift. All controls had fibre proportions within the
normal range.
TABLE 1 The physiological and quadriceps fibre characteristics of patients and controls
COPD Controls p-value COPD without fibre shift COPD with fibre
shift
p-value
Subjects n 38 23 25 13
Age years 68¡8 67¡8 0.38 68¡8 69¡6 0.64
Male 63 57 0.79 64 62 1.00
Smoking history pack-years 45 (36–60) 4 (0–10) ,0.0001 45 (35–59) 45 (37–82) 0.44
Smoking status 0.038 0.39
Current 18 0 24 8
Ex or never 82 100 76 92
FEV1 L 0.98¡0.44 2.95¡0.63 ,0.0001 0.94 (0.64–1.17) 0.75 (0.61–1.22) 0.24
FEV1 % pred 41¡18 110¡14 ,0.0001 41 (27–53) 33 (24–51) 0.52
Residual volume % of TLC 60¡9 38¡1 ,0.0001 60¡9 60¡9 0.92
TLCO % pred 41¡17 90¡14 ,0.0001 46¡17 33¡15 0.02
PaO2 kPa 9.4¡1.2 10.8¡1.4 ,0.0001 9.5¡1.3 9.3¡1.0 0.49
PaCO2 kPa 5.2¡0.7 5.2¡0.4 0.91 5.2¡0.6 5.3¡0.6 0.80
Body mass index kg?m-2 23.8¡3.6 26.3¡4.4 0.18 23.8¡3.7 23.7¡3.7 0.91
Fat-free mass kg 43¡8 51¡12 0.002 42¡7 44¡10 0.34
Fat-free mass index kg?m-2 15.6¡1.9 17.4¡2.4 0.002 15.6¡1.8 15.7¡2.1 0.84
Quadriceps MVC kg 27¡9 36¡10 ,0.0001 27 (22–33) 24 (18–33) 0.35
Quadriceps endurance T80 s 92¡41 137¡73 0.024 85 (78–113) 78 (66–90) 0.24
Locomotion time min?12 h-1 37 (21–52) 95 (61–131) ,0.0001 38 (22–66) 26 (17–43) 0.27
6-min walk test distance m 394¡108 617¡84 ,0.0001 416¡110 352¡93 0.08
Peak V9O2 mL?kg
-1?min-1 12.0¡3.4 23.9¡7.3 ,0.0001 12.2 (10.8–14.4) 9.9(9.1–10.8) 0.02
Data are presented as %, mean¡SD or median (interquartile range), unless otherwise stated. COPD: chronic obstructive pulmonary disease; FEV1: forced expiratory
volume in 1 s; % pred: % predicted; TLC: total lung capacity; TLCO: transfer factor of the lung for carbon monoxide; PaO2: arterial oxygen tension; PaCO2: arterial carbon
dioxide tension; MVC: maximal voluntary contraction; T80: force decline to 80% of initial response; V9O2: oxygen uptake.
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Characteristics of COPD patients with fibre shift compared
with COPD patients without fibre shift
Patients with fibre shift had a significantly lower transfer factor
of the lung for carbon monoxide, but not a lower forced
expiratory volume in 1 s, compared with patients without fibre
shift. In addition, patients with fibre shift had a poorer exercise
performance on the incremental cycle ergometry and a trend to
a reduced 6-min walking distance than those without fibre
shift, without group differences in FFMI or quadriceps
strength to account for this. Physical activity levels were not
significantly different between these groups (table 1).
All patients with fibre shift fulfilled the criteria for fibre shift
by having a low type I fibre proportion, with an increase in the
type IIa population without the type IIx fibre proportion
exceeding the normal range. Type I and II fibre CSA were not
different between patients with and without fibre shift (table 2
and fig. 1), consistent with no difference in FFMI between the
groups (table 1).
Expression of calcineurin and calcineurin modulators,
phospho-AMPK and PKA in COPD patients and controls
Calcineurin A expression was higher in quadriceps of COPD
patients than controls, and furthermore, was significantly
higher in patients with fibre shift than patients without fibre
shift (table 3, figs 2a and 3a). However, patients had signifi-
cantly lower MyH7 transcripts than controls and there was a
trend to lower MyH7 transcripts in patients with fibre shift
than without. There were no significant differences in
expression of calmodulin, 14-3-3 proteins, or MCIP1 mRNA.
Phospho-AMPK was not significantly different between COPD
patients and controls but the median amount was three-fold
higher in the COPD patients without fibre shift compared with
those with fibre shift (p50.005) (table 3, figs 2b and 3b).
Expression of PKA-a was not significantly different in COPD
patients and controls, or between patients with and without
fibre shift (table 3, figs 2c and 3c). a-tubulin levels were
not significantly different between patients and controls
TABLE 2 Fibre proportions and fibre cross-sectional area (CSA) of the quadriceps muscle of chronic obstructive pulmonary
disease (COPD) patients and healthy controls
COPD Controls p-value COPD without fibre shift COPD with fibre
shift
p-value
Subjects n 38 23 25 13
Type I fibres % 29¡13 54¡14 ,0.0001 37 (32–42) 13¡7 ,0.00011
Type I/IIa fibres % 3 (1–7) 0 (2–6) 0.22 3 (1–8) 3 (0–7) 0.96
Type IIa fibres % 60¡12 41¡14 ,0.0001 57 (49–60) 71¡12 ,0.0001
Type IIx fibres % 4 (1–7) 1 (0–4) 0.025 2 (1–5) 7 (2–20) 0.026
Type I fibre CSA mm2 5160¡1790 5650¡1410 0.27 4950¡1480 5580¡2290 0.31
Type I/IIa fibre CSA mm2 5060 (3600–6040) 5460 (4620–6530) 0.19 4800¡1510 5030¡1650 0.72
Type IIa fibre CSA mm2 3870¡1400 4570¡1600 0.08 3730¡1050 4150¡1930 0.39
Type IIx fibre CSA mm2 2680 (1740–3450) 5130 (3600–6950) ,0.0001 2870¡1230 2570¡907 0.47
Data are presented as mean¡SD or median (interquartile range), unless otherwise state. Fibre proportions are correct but do not add up to 100% as median values for
each fibre type may not be from the same individual.
TABLE 3 Protein expression of calcineurin A, protein kinase A-a subunit and phosphorylated AMP kinase and MEF2 DNA-
binding in quadriceps muscle from chronic obstructive pulmonary disease (COPD) patients and healthy controls
COPD Controls p- value COPD without fibre shift COPD with fibre shift p-value
Subjects n 38 23 25 13
Calcineurin A protein AU 0.82¡0.34# 0.60¡0.37" 0.036 0.74 (0.43–0.97) + 0.98 (0.69–1.30)1 0.03
MEF2 DNA-binding RLU 1710 (696–2320) 2660 (1830–3550) 0.004 1750 (928–2460) 1440 (329–2290) 0.29
Calmodulin AU 1.09¡0.66 1.05¡0.70 0.81 0.71 (0.56–1.38) 1.32 (0.63–1.67)e 0.19
MCIP mRNA AU 0.03 (0.03–0.05) 0.04 (0.03–0.06) 0.66 0.03 (0.03–0.05) 0.05 (0.03–0.08) 0.14
14-3-3 proteins AU 0.94 (0.64–1.48) 0.89 (0.43–1.11) 0.30 0.94 (0.72–1.48) 0.94 (0.38–2.02) 0.78
MyHC I mRNA AU 0.05 (0.03–0.06) 0.08 (0.04–0.10) 0.004 0.05 (0.04–0.07) 0.03 (0.02–0.05) 0.06
Phospho-AMPK-a protein AU 3.93 (1.82–7.95)## 2.37 (1.11–9.61) 0.64 7.08 (4.78–11.1)e 2.07 (1.73–3.24)e 0.005
PKA-a protein AU 1.28¡0.51 1.48¡0.58 0.18 1.17 (0.99–1.43) 2.1 (1.7–3.2) 0.93
Data are presented as mean¡SD or median (interquartile range), unless otherwise stated. Sample numbers are given where analysis was completed in less than a full set
of subjects. Figures are correct to 3 significant figures. MEF: myocyte enhancer factor; RLU: relative light unit; MCIP: modulatory calcineurin-interacting protein 1; MyHC
myosin heavy chain; phospho-AMPK: phosphorylated AMP kinase; PKA: protein kinase A. #: n534; ": n519; +: n523; 1: n511; e: n512; ##: n524.
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(54.9¡17.4 AU versus 48.2¡20.7 AU, p50.21), confirming
reports that a-tubulin is a valid loading control in COPD [30, 33].
MEF2 DNA-binding in nuclear extracts of quadriceps
muscle
MEF2 DNA-binding was significantly lower in muscle from
COPD patients compared to controls (table 3, fig. 2d), but
there was no difference between patients with and without
fibre shift.
Correlations between mediators, quadriceps oxidative fibre
proportion and quadriceps endurance in COPD
There was no correlation between calcineurin and quadriceps
type I fibre proportion (r5 -0.17, p50.33) (fig. 4a) or quad-
riceps endurance (r5 -0.05, p50.80) in patients or in patients
and controls combined (r5 -0.18, p50.21 and r5 -0.05,
p50.75, respectively). Modulators of calcineurin activity,
PKA and MEF2 were not correlated with muscle histology or
muscle endurance. Phospho-AMPK, however, was strongly
correlated with quadriceps type I fibre proportion (r50.54,
p50.006) (fig. 4b) and quadriceps endurance (r50.47,
p50.029) (fig. 4c) in patients.
When patients and controls were combined, MEF2 was
significantly correlated with quadriceps strength (r50.43,
p,0.0001), FFMI (r50.27, p50.033) and exercise performance
(6-min walk distance r50.34, p50.008 and peak oxygen uptake
on cycle ergometry (r50.32, p50.012)) (fig. E1).
DISCUSSION
This is the first study investigating potential molecular
mechanisms underlying the reduced quadriceps muscle
oxidative fibres and energy stores that contribute to poor
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FIGURE 2. a) Calcineurin protein A expression was higher in the quadriceps of chronic obstructive pulmonary disease (COPD) patients with fibre shift (FS) than patients
without fibre shift (0.98 (0.69–1.30) AU versus 0.74 (0.43–0.97) AU, p50.030), and higher in COPD patients overall compared to controls (0.82¡0.34 AU versus
0.60¡0.37 AU, p50.036). b) Phospho-AMP kinase protein (phospho-AMPK) was three-fold lower in the COPD patients with fibre shift than those without fibre shift (2.07
(1.73–3.24) AU versus 7.08 (4.78–11.1) AU, p50.005), although levels were not significantly different between COPD patients overall compared to controls (3.93 (1.32–
7.95) AU versus 2.37 (1.11–9.61) AU, p50.64). c) Protein kinase A protein was not significantly different between any group. d) There was no significant difference in myocyte
enhancer factor (MEF)2 capable of binding DNA between patients with and without fibre shift (1440 (329–2290) relative light units (RLU) versus 1750 (928–2460) RLU,
p50.29), although muscle MEF2 DNA-binding was lower in COPD patients than in controls (1710 (696–2320) RLU versus 2660 (1830–3550) RLU, p50.004). #: p50.036;
": p50.03; +: p50.005; 1: p50.04.
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demonstrated that phospho-AMPK is lower in the quadriceps
muscle of COPD patients with fibre shift than patients without
fibre shift. Furthermore, levels correlate with quadriceps
endurance in patients. Reduced muscle AMPK expression
may, therefore, contribute to reduced quadriceps endurance in
COPD. Unexpectedly, calcineurin expression was increased in
COPD patients with fibre shift compared to patients without
fibre shift and healthy controls. Despite this adaptation,
downstream nuclear MEF2 capable of binding to DNA and
myosin heavy chain I transcription were reduced in patients
compared to controls.
We did not find that COPD patients with fibre shift were
significantly less active than those without fibre shift (table 1),
suggesting that other factors must be important in driving fibre
shift. Patients with fibre shift had a greater degree of
emphysema, but not greater airflow obstruction or resting
hypoxaemia, than patients without fibre shift, although our
data do not preclude transient hypoxia, perhaps sleep or
exercise induced, as a stimulus to fibre shift. Certainly chronic
hypoxia reduces muscle oxidative fibres in animals [34].
Alternatively, emphysema and fibre shift could develop
through a common mechanism, and may not be linked
through muscle hypoxia.
Significance of the findings
We have consolidated previous data highlighting the im-
portance of muscle oxidative phenotype to exercise endurance
in COPD [35] and in health [36], by demonstrating that patients
with fibre shift have poorer exercise performance than patients
without fibre shift, independent of differences in muscle mass
or quadriceps strength (table 1). Quadriceps fatigue during
exercise has been reported in a significant proportion of
patients with COPD, who are poorly responsive to broncho-
dilators during exercise [1] presumably because performance is
limited by muscle endurance rather than ventilatory limitation.
Our finding that phospho-AMPK levels correlated not just
with quadriceps type I fibre proportion, but also with
quadriceps endurance in COPD patients (fig. 4), is therefore
important, as increasing these levels using a pharmacological
agent such as metformin [37] or a nutritional supplement such
as resveratrol [38], for example, could potentially enhance
exercise performance in patients with fibre shift, in whom
muscle fatigue is likely to pose a limitation.
We had expected an adaptive increase in phospho-AMPK in
the muscle of patients, as an appropriate response to the
metabolic and oxidative stress that occurs in COPD [39, 40].
This was observed in patients without fibre shift, who showed
a three-fold increase in phospho-AMPK levels compared to
controls, but not in patients with fibre shift (table 3). In
addition, we have previously shown that downstream of
AMPK, peroxisome proliferator-activated receptor (PPAR)-d, a
transcription factor promoting type I fibre differentiation in
















FIGURE 3. Western blot images illustrating the finding that a) calcineurin levels
were higher while b) phosphorylated AMP kinase (phospho-AMPK)-a protein levels
were lower in chronic obstructive pulmonary disease (COPD) patients with fibre shift
(+FS) than patients without fibre shift (-FS), while there was no significant difference
in c) protein kinase A (PKA) protein between COPD patients with fibre shift, patients
























































































































































































FIGURE 4. a) There was no significant correlation between type I fibre proportion and calcineurin in patients alone (r5 -0.17, p50.33) or when patients and controls
were combined (r5 -0.18, p50.21). Phospho-AMP kinase (phospho-AMPK) was strongly correlated with b) quadriceps type I fibre proportion (r50.54, p50.006) and c)
quadriceps endurance measured nonvolitionally (r50.47, p50.029) in patients. Modulators of calcineurin activity and protein kinase A were not correlated with muscle
histology or quadriceps endurance. COPD: chronic obstructive pulmonary disease. T80: force decline to 80% of initial response.
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The paradoxical increase in calcineurin expression in COPD
patients, particularly those with fibre shift (table 3), has a
number of possible explanations. It could be the result of
feedback in response to reduced calcineurin activity, from
reduced muscle activity [8] (though we did not find an
association between physical activity and calcineurin) or
resistance to calcineurin activity downstream. The finding of
increased phosphorylated AKT in COPD muscle by DOUCET
et al. [30] supports a resistance to calcineurin activity, since
AKT is dephosphorylated by activated calcineurin [43].
Alternatively, the increase in calcineurin expression could be
a compensatory response to fibre shift generated due to
disruption of an alternative signalling pathway. The enhanced
expression could also be a response to muscle atrophy in view
of calcineurin’s possible, but debated, role in skeletal muscle
regeneration and hypertrophy [44, 45]. Interestingly, calci-
neurin may have different effects depending on the disease
context: in the mdx mouse model of Duchenne muscular
dystrophy, calcineurin activation has a protective effect [46],
whereas in limb-girdle muscular dystrophy models calcineurin
disruption is beneficial [47]. The influence of calcineurin on
muscle phenotype is clearly complex and further work on
downstream signalling in patient muscle may indicate whether
augmenting this pathway could be of therapeutic benefit to
COPD patients.
MEF2 is a key regulator of muscle-specific gene expression,
and is co-activated by PPAR-c co-activator 1-a when involved
in type I fibre-specific gene expression [48]. Although DNA-
binding is a prerequisite for transcriptional activity, additional
factors influence MEF2 activity such as sumoylation and
acetylation [49] (increase activity) and interaction with class
II histone deacetylases, HDAC4 and HDAC5 [50], which are
activated in muscle by inactivity and decrease MEF2 activity.
We have previously shown increased HDAC4 in the quad-
riceps muscle of COPD patients compared to controls [18], and
here MEF2 DNA-binding was lower in patients than controls
and associated with quadriceps strength, muscle mass and
exercise performance (table 3 and fig. E1). These findings may
have been the result of lower physical activity in patients than
controls; we were unable to match these groups for activity
since reduced physical activity is so intrinsic to the disease,
occurring even in mild COPD [17], not only the moderate to
very severe group we studied. The lack of difference in
patients with and without fibre shift, who did not differ in
physical activity levels, suggest that any signalling dis-
turbances leading to fibre shift occur independently of a
reduction in nuclear MEF2 able to bind DNA.
In stable COPD patients at rest, PKA expression was not
chronically altered (table 3). However, this does not exclude
differences in PKA activity or PKA transcription/post-transla-
tional modification during exercise since patients experience
greater metabolic stress than controls [39].
Critique of the method
As is common with human work, the study is descriptive and
observational; causality cannot be confirmed without selective
manipulation of each signalling factor in patients. We also
report expression of the various enzymes and modulators and
not activity, which is influenced by factors in addition to
expression, as we have alluded to. We attempted to measure
calcineurin activity using a phosphatase testing kit (Profluor kit 5,
Promega, Madison, WI, USA) and found it impossible to isolate the
effects of calcineurin from phosphatases 2A and 2C, even utilising
inhibitors such as okadaic acid. To our knowledge, calcineurin
activity in human skeletal muscle has not been reported previously.
There are limitations to most accepted techniques for measuring
transcription factor activity. Transcription factor ELISAs, like
electrophoretic mobility shift assays, measure the amount of
transcription factor translocated to the nucleus in an appropriate
configuration and affinity for DNA to bind, but not the amount
bound to DNA in vivo at the time of the biopsy. The technique of
chromatin immunoprecipitation, not previously performed on
human muscle, can quantify transcription factor bound to DNA
in vivo but still does not quantify transcriptional activity, which
may be altered by presence of cofactors, etc.
It could be argued that the differences in calcineurin and
phospho-AMPK levels between patients with and without
fibre shift are simply the result of differential expression
between type I and type II fibres. Were this the case, we would
have found significant differences in phospho-AMPK between
patients and controls, and correlations between phospho-
AMPK and calcineurin and type I fibre proportion in controls,
which we did not. Also, to our knowledge, there are no
published data on fibre type differences in calcineurin and
AMPK protein expression in human muscle, although in
human skeletal muscle, mRNA levels of the inhibitory
AMPK-c subunit [51] are higher in glycolytic fibres.
In summary, phospho-AMPK was reduced in the quadriceps
of stable patients with COPD who have oxidative to glycolytic
fibre type shift, reduced muscle endurance and reduced
exercise performance. Therefore, increasing phospho-AMPK
in skeletal muscle of COPD patients with fibre shift may be a
viable therapeutic approach. Conversely, calcineurin expres-
sion was increased in patients with fibre shift in the
quadriceps, which we suggest is the result of resistance to
calcineurin signalling, in which case increasing expression
further may not be an appropriate therapeutic strategy. MEF2
DNA-binding does not appear to differentiate patients with
and without fibre shift, but is associated with muscle mass and
strength, and therefore may be best explored in patients with
marked quadriceps wasting and weakness.
SUPPORT STATEMENT
S.A. Natanek was funded by a Wellcome Clinical Fellowship (grant
number 079686). H.R. Gosker was funded by a Netherlands Asthma
Foundation grant (grant number NAF 3.4.05.038). G.S. Marsh was
funded by an award from GSK to Imperial College. N.S. Hopkinson is
a Higher Education Funding Council for England (HEFCE) clinical
senior lecturer. The study was carried out within the National Institute
for Health Research Respiratory Biomedical Research Unit at the Royal
Brompton Hospital and Imperial College (London, UK), which part
funds M.I. Polkey’s salary.
STATEMENT OF INTEREST
Conflict of interest information can be found alongside the online
version of this article at www.erj.ersjournals.com
ACKNOWLEDGEMENTS
We would like to thank Winston Banya, in the Statistics Department of
the Royal Brompton Hospital (London, UK), for his help with the
statistical analysis, Derek Cramer, Mark Unstead and the lung function
S.A. NATANEK ET AL. COPD
c
EUROPEAN RESPIRATORY JOURNAL VOLUME 41 NUMBER 6 1281
department at the Royal Brompton Hospital, London, for performing the
pulmonary function tests, and Kathleen Daenen at The University
Hospital Maastricht (Maastricht, the Netherlands) for the cryosectioning.
REFERENCES
1 Saey D, Debigare R, LeBlanc P, et al. Contractile leg fatigue after
cycle exercise: a factor limiting exercise in patients with chronic
obstructive pulmonary disease. Am J Respir Crit Care Med 2003;
168: 425–430.
2 Swallow EB, Gosker HR, Ward KA, et al. A novel technique for
nonvolitional assessment of quadriceps muscle endurance in
humans. J Appl Physiol 2007; 103: 739–746.
3 Gosker HR, Zeegers MP, Wouters EF, et al. Muscle fibre type
shifting in the vastus lateralis of patients with COPD is associated
with disease severity: a systematic review and meta-analysis.
Thorax 2007; 62: 944–949.
4 Koechlin C, Couillard A, Simar D, et al. Does oxidative stress alter
quadriceps endurance in chronic obstructive pulmonary disease?
Am J Respir Crit Care Med 2004; 169: 1022–1027.
5 Rich PR. The molecular machinery of Keilin’s respiratory chain.
Biochem Soc Trans 2003; 31: 1095–1105.
6 Eker S, Ayaz L, Tamer L, et al. Leptin, visfatin, insulin resistance,
and body composition change in chronic obstructive pulmonary
disease. Scand J Clin Lab Invest 2010; 70: 40–44.
7 Lauritzen HP, Schertzer JD. Measuring GLUT4 translocation in
mature muscle fibers. Am J Physiol Endocrinol Metab 2010; 299:
E169–E179.
8 Zierath JR, Hawley JA. Skeletal muscle fiber type: influence on
contractile and metabolic properties. PLoS Biol 2004; 2: e348.
9 Long YC, Zierath JR. Influence of AMP-activated protein kinase
and calcineurin on metabolic networks in skeletal muscle. Am J
Physiol Endocrinol Metab 2008; 295: E545–E552.
10 Rothermel BA, Vega RB, Williams RS. The role of modulatory
calcineurin-interacting proteins in calcineurin signaling. Trends
Cardiovasc Med 2003; 13: 15–21.
11 Chin ER, Olson EN, Richardson JA, et al. A calcineurin-dependent
transcriptional pathway controls skeletal muscle fiber type. Genes
Dev 1998; 12: 2499–2509.
12 Abbasi S, Lee JD, Su B, et al. Protein kinase-mediated regulation
of calcineurin through the phosphorylation of modulatory
calcineurin-interacting protein 1. J Biol Chem 2006; 281: 7717–7726.
13 Chow CW, Davis RJ. Integration of calcium and cyclic AMP
signaling pathways by 14-3-3. Mol Cell Biol 2000; 20: 702–712.
14 Narkar VA, Downes M, Yu RT, et al. AMPK and PPARd agonists
are exercise mimetics. Cell 2008; 134: 405–415.
15 Zheng D, MacLean PS, Pohnert SC, et al. Regulation of muscle
GLUT-4 transcription by AMP-activated protein kinase. J Appl
Physiol 2001; 91: 1073–1083.
16 Nielsen JN, Wojtaszewski JF. Regulation of glycogen synthase
activity and phosphorylation by exercise. Proc Nutr Soc 2004; 63:
233–237.
17 Shrikrishna D, Patel M, Tanner RJ, et al. Quadriceps wasting and
physical inactivity in patients with COPD. Eur Respir J 2012; 40:
1115–1122.
18 Lewis A, Riddoch-Contreras J, Natanek SA, et al. Downregulation
of the serum response factor/miR-1 axis in the quadriceps of
patients with COPD. Thorax 2012; 67: 26–34.
19 Riddoch-Contreras J, George T, Natanek SA, et al. p38 mitogen-
activated protein kinase is not activated in the quadriceps of
patients with stable chronic obstructive pulmonary disease. COPD
2012; 9: 142–150.
20 Miller MR, Hankinson J, Brusasco V, et al. Standardisation of
spirometry. Eur Respir J 2005; 26: 319–338.
21 Wanger J, Clausen JL, Coates A, et al. Standardisation of the
measurement of lung volumes. Eur Respir J 2005; 26: 511–522.
22 Macintyre N, Crapo RO, Viegi G, et al. Standardisation of the
single-breath determination of carbon monoxide uptake in the
lung. Eur Respir J 2005; 26: 720–735.
23 Steiner MC, Barton RL, Singh SJ, et al. Bedside methods versus dual
energy X-ray absorptiometry for body composition measurement
in COPD. Eur Respir J 2002; 19: 626–631.
24 Pitta F, Troosters T, Spruit MA, et al. Activity monitoring for
assessment of physical activities in daily life in patients with
chronic obstructive pulmonary disease. Arch Phys Med Rehabil
2005; 86: 1979–1985.
25 Edwards RH, Young A, Hosking GP, et al. Human skeletal muscle
function: description of tests and normal values. Clin Sci Mol Med
1977; 52: 283–290.
26 ATS Committee on Proficiency Standards for Clinical Pulmonary
Function Laboratories. ATS statement: guidelines for the six-
minute walk test. Am J Respir Crit Care Med. 2002; 166: 111–117.
27 Buchfuhrer MJ, Hansen JE, Robinson TE, et al. Optimizing the
exercise protocol for cardiopulmonary assessment. J Appl Physiol
1983; 55: 1558–1164.
28 Bergstrom J. Percutaneous needle biopsy of skeletal muscle in
physiological and clinical research. Scand J Clin Lab Invest 1975; 35:
609–616.
29 Russell AP, Wadley G, Hesselink MK, et al. UCP3 protein
expression is lower in type I, IIa and IIx muscle fiber types of
endurance-trained compared to untrained subjects. Pflugers Arch
2003; 445: 563–569.
30 Doucet M, Russell AP, Leger B, et al. Muscle atrophy and
hypertrophy signaling in patients with chronic obstructive
pulmonary disease. Am J Respir Crit Care Med 2007; 176: 261–269.
31 Vandesompele J, De Preter K, Pattyn F, et al. Accurate normal-
ization of real-time quantitative RT-PCR data by geometric
averaging of multiple internal control genes. Genome Biol 2002; 3:
RESEARCH0034.
32 Gosker HR, Engelen MP, van Mameren H, et al. Muscle fiber type
IIX atrophy is involved in the loss of fat-free mass in chronic
obstructive pulmonary disease. Am J Clin Nutr 2002; 76: 113–119.
33 Plant PJ, Brooks D, Faughnan M, et al. Cellular markers of muscle
atrophy in chronic obstructive pulmonary disease (COPD). Am J
Respir Cell Mol Biol 2010; 42: 461–471.
34 Ishihara A, Itoh K, Itoh M, et al. Effect of hypobaric hypoxia on rat
soleus muscle fibers and their innervating motoneurons: a review.
Jpn J Physiol 2000; 50: 561–568.
35 Maltais F, Simard AA, Simard C, et al. Oxidative capacity of the
skeletal muscle and lactic acid kinetics during exercise in normal
subjects and in patients with COPD. Am J Respir Crit Care Med
1996; 153: 288–293.
36 Thomas TR, Zebas CJ, Bahrke MS, et al. Physiological and
psychological correlates of success in track and field athletes.
Br J Sports Med 1983; 17: 102–109.
37 Musi N, Hirshman MF, Nygren J, et al. Metformin increases AMP-
activated protein kinase activity in skeletal muscle of subjects with
type 2 diabetes. Diabetes 2002; 51: 2074–2081.
38 Timmers S, Konings E, Bilet L, et al. Calorie restriction-like effects
of 30 days of resveratrol supplementation on energy metabolism
and metabolic profile in obese humans. Cell Metab, 14: 612–622.
39 Steiner MC, Evans R, Deacon SJ, et al. Adenine nucleotide loss in
the skeletal muscles during exercise in chronic obstructive
pulmonary disease. Thorax 2005; 60: 932–936.
40 Barreiro E, Rabinovich R, Marin-Corral J, et al. Chronic endurance
exercise induces quadriceps nitrosative stress in patients with
severe COPD. Thorax 2009; 64: 13–19.
41 Wang YX, Zhang CL, Yu RT, et al. Regulation of muscle fiber type
and running endurance by PPARd. PLoS Biol 2004; 2: e294.
42 Remels AH, Schrauwen P, Broekhuizen R, et al. Peroxisome
proliferator-activated receptor expression is reduced in skeletal
muscle in COPD. Eur Respir J 2007; 30: 245–252.
COPD S.A. NATANEK ET AL.
1282 VOLUME 41 NUMBER 6 EUROPEAN RESPIRATORY JOURNAL
43 Ni YG, Wang N, Cao DJ, et al. FoxO transcription factors activate
Akt and attenuate insulin signaling in heart by inhibiting
protein phosphatases. Proc Natl Acad Sci USA 2007; 104: 20517–
20522.
44 Michel RN, Dunn SE, Chin ER. Calcineurin and skeletal muscle
growth. Proc Nutr Soc 2004; 63: 341–349.
45 Schiaffino S, Serrano A. Calcineurin signaling and neural control
of skeletal muscle fiber type and size. Trends Pharmacol Sci 2002; 23:
569–575.
46 Chakkalakal JV, Harrison MA, Carbonetto S, et al. Stimulation of
calcineurin signaling attenuates the dystrophic pathology in mdx
mice. Hum Mol Genet 2004; 13: 379–388.
47 Parsons SA, Millay DP, Sargent MA, et al. Genetic disruption
of calcineurin improves skeletal muscle pathology and cardiac
disease in a mouse model of limb-girdle muscular dystrophy.
J Biol Chem 2007; 282: 10068–10078.
48 Lin J, Wu H, Tarr PT, et al. Transcriptional co-activator PGC-1 a drives
the formation of slow-twitch muscle fibres. Nature 2002; 418: 797–801.
49 Gregoire S, Tremblay AM, Xiao L, et al. Control of MEF2
transcriptional activity by coordinated phosphorylation and
sumoylation. J Biol Chem 2006; 281: 4423–4433.
50 Mihaylova MM, Vasquez DS, Ravnskjaer K, et al. Class IIa histone
deacetylases are hormone-activated regulators of FOXO and
mammalian glucose homeostasis. Cell, 145: 607–621.
51 Mahlapuu M, Johansson C, Lindgren K, et al. Expression profiling
of the c-subunit isoforms of AMP-activated protein kinase
suggests a major role for c3 in white skeletal muscle. Am J Phys
Endocrinol Metab 2004; 286: E194–E200.
S.A. NATANEK ET AL. COPD
EUROPEAN RESPIRATORY JOURNAL VOLUME 41 NUMBER 6 1283
